Eli Lilly (LLY.US), a leading U.S. healthcare company, has issued a warning that the core active ingredient in its blockbuster weight-loss drug Zepbound may pose significant health risks to patients when mixed with vitamin B12. This specific formulation is currently being sold by drug compounding facilities in the United States. In a statement released on Thursday, Eli Lilly reported that testing of these compounded products revealed the presence of "significant levels of a specific impurity." This impurity results from a chemical reaction between the vitamin and tirzepatide, the active ingredient in Lilly's weight-loss medication. The U.S. pharmaceutical manufacturer stated, "Anyone who obtains a tirzepatide-B12 product from a compounding pharmacy, telehealth company, spa, or any other source should be aware that they may be using a product with potential safety risks that are unknown." The company also referenced potential toxicity and harmful immune system overreactions. Similar to its strongest competitor in the weight-loss drug sector, Novo Nordisk, Eli Lilly faces pressure from cheaper compounded and copycat versions. These replicas of weight-loss and diabetes injection drugs bypass the stringent regulatory approval processes required for branded or generic pharmaceuticals. For a period, these compounded and copycat drugs were permitted for sale in the U.S. market to address severe supply shortages during the initial surge in demand for weight-loss injections. Shortly thereafter, the U.S. Food and Drug Administration (FDA) declared the shortage over, meaning these discounted compounded and copycat versions are no officially longer authorized for sale. Despite this, some compounding and copycat operations continue to exploit a regulatory loophole that allows them to create custom formulations—for instance, by slightly altering dosages or adding other ingredients like vitamin B12. It is understood that Eli Lilly is urging the FDA to recall all compounded versions of tirzepatide that are mixed with additives not tested to official standards. Eli Lilly indicated that its recent testing uncovered other critical safety concerns, such as bacterial contamination and high levels of the toxic component endotoxin. The company stated that these compounded versions are being mixed with chemicals like glycine, pyridoxine, nicotinamide, and carnitine, creating a range of new, untested combination drugs. The company is urging the FDA to recall all compounded drugs containing untested additives. The FDA had previously issued warnings to over 30 telehealth companies regarding misleading marketing of compounded GLP-1 drugs, indicating a convergence of regulatory enforcement priorities with those of branded drug manufacturers. From a sales and earnings growth perspective, Eli Lilly's safety warning regarding compounded "tirzepatide+B12" weight-loss drugs is generally positive for the sales outlook of its branded weight-loss medications. This is particularly beneficial for the recovery of Zepbound's market share and pricing power in the U.S. cash-pay market. For Eli Lilly, if the FDA recalls these untested compounded products, the demand previously diverted to low-cost compounded tirzepatide is more likely to return to compliant, branded channels. However, given that the U.S. weight-loss drug market is itself experiencing price competition and cash-pay pressures, this does not necessarily equate to an immediate surge in new demand.
Comments